Clinical trialNCT01975116CompletedPhase 1Interventional

p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors

SponsorPediatric Brain Tumor ConsortiumEnrollment18Anaplastic AstrocytomaAnaplastic OligodendrogliomaBrainstem TumorsChoroid Plexus NeoplasmsGiant Cell GlioblastomaGlioblastoma+4 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I trial studies the side effects and best dose of azurin-derived cell-penetrating peptide p28 (p28) in treating patients with recurrent or progressive central nervous system tumors. Drugs used in chemotherapy, such as azurin-derived cell-penetrating peptide p28, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Stewart Goldman
Pediatric Brain Tumor Consortium
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Children'S Hospital Los Angeles
Los Angeles, California, United States
Lucile Packard Children'S Hospital Stanford University
Palo Alto, California, United States
Children'S National Medical Center
Washington D.C., District of Columbia, United States
Lurie Children'S Hospital-Chicago
Chicago, Illinois, United States
National Cancer Institute Pediatric Oncology Branch
Bethesda, Maryland, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Cincinnati Children'S Hospital Medical Center
Cincinnati, Ohio, United States
Children'S Hospital of Pittsburgh of Upmc
Pittsburgh, Pennsylvania, United States
St. Jude Children'S Research Hospital
Memphis, Tennessee, United States
Baylor College of Medicine
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Azurin-derived cell-penetrating peptide p28

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 2013
Primary completion: 30 Apr 2015
Completion: 30 Apr 2015
Last update posted: 7 Aug 2017
Registered enrollment: 18
Registry id: NCT01975116

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.